microRNA-21 Expression is Elevated in Esophageal Adenocarcinoma After Neoadjuvant Chemotherapy

REFERENCES

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–2150.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360–367; discussion 368–369.
   PubMed Web of Science ®Google Scholar
• Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19:5598–5606.
   PubMed Web of Science ®Google Scholar
• Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group. EUROCARE-3: Survival of cancer patients diagnosed 1990–94–results and commentary. Ann Oncol 2003;14(Suppl. 5):v61–v118.
   PubMed Web of Science ®Google Scholar
• Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: Evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 2004;11:665–673.
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Brabender J, Grimminger P, Schroder W, Holscher AH. Predicting response to neoadjuvant therapy in esophageal cancer. Expert Rev Anticancer Ther 2011;11:1449–1455.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006;66:7390–7394.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• Kozomara A, Griffiths-Jones S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68–D73.
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–833.
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060–1065.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Krichevsky AM, Gabriely G. miR-21: A small multi-faceted RNA. J Cell Mol Med 2009;13:39–53.
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257–2261.
   PubMed Web of Science ®Google Scholar
• Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009;15: 1915–1922.
   PubMed Web of Science ®Google Scholar
• Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011;128:132–143.
   PubMed Web of Science ®Google Scholar
• Ma WJ, Lv GD, Tuersun A, Liu Q, Liu H, Zheng ST, Huang CG, Feng JG, Wang X, Lin RY, Sheyhidin I, Lu XM. Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep 2011;38:3253–3260.
   PubMed Web of Science ®Google Scholar
• Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res 2009;15:6192–6200.
   PubMed Web of Science ®Google Scholar
• Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Ogawa R, Katada T, Harata K, Tanaka T, Shiozaki M, Fujii Y. MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Rep 2009;2:235–239.
   Web of Science ®Google Scholar
• Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010;14:1170–1179.
   PubMed Web of Science ®Google Scholar
• Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K, Fujii Y. MicroRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009;34:537–542.
   PubMed Web of Science ®Google Scholar
• Tchernitsa O, Kasajima A, Schäfer R, Kuban RJ, Ungethüm U, Györffy B, Neumann U, Simon E, Weichert W, Ebert MP, Röcken C. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 2010;222:310–319.
   PubMed Web of Science ®Google Scholar
• Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, Zhou Y, Du C, He X, Shi Y. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011;17:7574–7583.
   PubMed Web of Science ®Google Scholar
• Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680–2686.
   PubMed Web of Science ®Google Scholar
• Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, HE Cohn, Rosato Sr. FE, Berger AC. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res 2008;146:11–15.
   PubMed Web of Science ®Google Scholar
• Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ, Sloof GW. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology 2005;236:841–851.
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Wohrer A, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ, Sloof GW. Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 2012;30: 615–621.
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wohrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, Preusser M. Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. J Neurooncol 2013;112:347–354.
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Wohrer A, Jungwirth S, Marosi C, Fischer P, Preusser M. Blood alterations preceding clinical manifestation of glioblastoma. Cancer Invest 2012;30:625–629.
   PubMed Web of Science ®Google Scholar